<DOC>
	<DOCNO>NCT01478074</DOCNO>
	<brief_summary>This single-center open-label phase I clinical trial deliver haploidentical natural killer ( NK ) cell mature ex vivo ALT-801 follow intravenous infusion ALT-801 patient relapsed/refractory Acute Myeloid Leukemia ( AML ) . The study conduct M.D . Anderson Cancer Center ( MDACC ) MDACC Children 's Cancer Hospital Houston , Texas .</brief_summary>
	<brief_title>ALT-801-activated Natural Killer Cells After FLAG Induction Acute Myeloid Leukemia</brief_title>
	<detailed_description>Hematopoietic stem cell transplantation ( SCT ) effective treatment acute myeloid leukemia ( AML ) myelodysplastic syndrome ( MDS ) . For patient transplant first remission low risk MDS , approximately 60 % patient achieve long-term disease free survival . Patients relapse leukemia poor outcome ; long-term disease free survival rate relapse AML 5-10 % without hematopoietic stem cell transplantation ( HSCT ) . With HSCT , survival relapse approach 40 % , success depend greatly whether patient remission time transplant . Many relapse patient refractory chemoresistant disease never attain remission eligible potentially curative HSCT , develop significant complicate comorbidities prolong intensive reinduction disease . Thus , improved strategy achieve remission relapse patient prior transplantation critical improving survival patient . Relapsed/refractory AML require remission prior allogeneic HSCT optimal survival , respond poorly chemotherapy . Human leukocyte antigen ( HLA ) -haploidentical , NK-enriched peripheral blood cell infusion may augment induction chemotherapy patient poor prognosis AML , significant toxicity relate IL-2 infusion give optimal NK cell activity . The purpose trial estimate toxicity feasibility treat relapsed/refractory AML FLAG chemotherapy follow haploidentical donor-derived natural killer ( NK ) cell use ALT-801 ex vivo vivo NK cell activation alternative interleukin-2 ( IL-2 ) . ALT-801 genetically engineer fusion protein , , single protein make combine DNA two different gene . ALT-801 combination IL-2 ( important protein stimulate immune cell ) bind portion recognize tumor cell . The primary objective study evaluate safety feasibility infuse allogeneic donor NK cell product ALT-801 following FLAG preparative regimen treat relapsed/refractory acute myelogenous leukemia . The primary endpoint toxicity absence NK cell Product ALT-801-related grade 2 toxicity , exclude grade 2 fever , rigor/chills , fatigue , vomiting/nausea , pruritus/itching , electrolyte imbalance , hypoalbuminemia lymphopenia within 21 day ALT-801 NK cell product infusion . The primary endpoint feasibility define able infuse NK-cells maximum tolerate cell dose high dose level day 0 complete 8 planned dos ALT-801 , safety exceed toxicity limit , great equal 7 10 subject .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Recipient 1 . Patients relapse AML , include CNS disease previous hematopoietic stem cell transplantation , primary refractory AML ( primary AML fail remission least two cycle induction therapy ) 2 . For patient Cohorts 2 4 , availability haploidentical family peripheral blood stem cell donor select best possible KIR reactivity 3 . Patient 2 59 year age , inclusive 4 . Patient must recover treatmentrelated toxicity prior cytotoxic agent receive 4 week prior begin treatment protocol , exception cytopenia result persistent disease , alopecia 5 . Zubrod performance scale ( Refer Appendix C ) ≤ 2 Lansky ( Refer Appendix D ) &gt; 60 6 . Adequate renal function define : For adult serum creatinine &lt; 2 mg/dL For child serum creatinine &lt; 2 mg/dL &lt; 2 time upper limit normal ( ULN ) age ( ever less ) If abnormal creatinine level , 24h creatinine clearance &gt; 60 mL/min/1.73m^2 7 . Adequate liver function , define : Total bilirubin ≤ 2 mg/dL SGPT ( ALT ) ≤ 2.5 x ULN age ( unless Gilbert 's disease abnormal liver function due primary disease ) 8 . Pulmonary symptom control medication pulse oximetry &gt; 92 % room air 9 . New York Heart Association classification &lt; III 10 . Negative serum test rule pregnancy within 2 week prior registration female childbearing potential ( non childbearing potential define premenarchal , great one year postmenopausal , surgically sterilize ) 11 . Sexually active male female childbearing potential must agree use form contraception consider effective medically acceptable Investigator 12 . Negative serology human immunodeficiency virus ( HIV ) Recipient 1 . Investigational therapy 4 week prior begin treatment protocol 2 . Congestive heart failure &lt; 6 month prior screen 3 . Unstable angina pectoris &lt; 6 month prior screen 4 . Myocardial infarction &lt; 6 month prior screen Donor 1 . Related recipient ( sibling , parent , offspring , offspring sibling ) 2 . HLAhaploidentical recipient ( need retested already perform previously , provide copy original result available ) 3 . Able willing undergo apheresis 4 . Willing donate blood baseline chimerism assessment 5 . Negative serum test rule pregnancy within two week prior registration female childbearing potential ( non childbearing potential define premenarchal , great one year postmenopausal , surgically sterilize ) 6 . Donor must meet institutional eligibility criterion allogeneic blood stem cell donation include infectious disease screen panel ( Hepatitis B , Hepatitis C , HIV , CMV , West Nile Virus ) CBC , differential platelet study 7 . Donor must meet stem cell donor eligibility criterion set forth 21 CFR 1271 subpart C 8 . The preferred Donor select alloreactive available haploidentical relate donor basis predict NK cell alloreactivity use Recipient Donor HLA type . If necessary , best equally alloreactive donor determine Donor KIR type . NK alloreactivity define A KIR gene present Donor NK cell HLA haplotype ( KIR ligand ) KIR receptor question absent Recipient , HLA haplotype ( KIR ligand ) KIR receptor question present Donor Donor 1 . Active infection ( define antimicrobial therapy and/or febrile ) 2 . Pregnant females 3 . Breastfeeding female</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Relapsed leukemia</keyword>
	<keyword>Refractory leukemia</keyword>
	<keyword>Natural Killer Cells</keyword>
	<keyword>Adoptive immunotherapy</keyword>
	<keyword>NK cell infusion</keyword>
	<keyword>Haploidentical</keyword>
	<keyword>KIR mismatch</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>ALT-801</keyword>
</DOC>